GlaxoSmithKline PLC Director/PDMR Shareholding (4072W)
16 Abril 2019 - 11:35AM
UK Regulatory
TIDMGSK
RNS Number : 4072W
GlaxoSmithKline PLC
16 April 2019
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. Details of PDMR/person closely associated with them
('PCA')
=============================================================================================================
a) Name Ms E Walmsley
===== ========================================================= ==================================================
b) Position/status Chief Executive Officer
===== ========================================================= ==================================================
c) Initial notification/ Initial notification
amendment
===== ========================================================= ==================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
===== =============================================================================================================
a) Name GlaxoSmithKline plc
===== ========================================================= ==================================================
b) LEI 5493000HZTVUYLO1D793
===== ========================================================= ==================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
===== =============================================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
===== ========================================================= ==================================================
b) Nature of the Increase in interest in Ordinary Shares
transaction following the re-investment of dividends
paid to shareholders on 11 April 2019 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan.
===== ========================================================= ==================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.6560 908.000
----------
GBP15.6560 260.000
----------
GBP15.6560 912.000
----------
GBP15.6560 260.000
----------
===== ========================================================= ==================================================
d) Aggregated information
Aggregated volume 2340.000
Price GBP15.6560
===== ========================================================= ==================================================
e) Date of the transaction 2019-04-12
===== ========================================================= ==================================================
f) Place of the London Stock Exchange (XLON)
transaction
===== ========================================================= ==================================================
1. Details of PDMR/person closely associated with them
('PCA')
===== =============================================================================================================
a) Name Dr H Barron
===== ========================================================= ==================================================
b) Position/status Chief Scientific Officer and President,
R&D
===== ========================================================= ==================================================
c) Initial notification/ Initial notification
amendment
===== ========================================================= ==================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
===== =============================================================================================================
a) Name GlaxoSmithKline plc
===== ========================================================= ==================================================
b) LEI 5493000HZTVUYLO1D793
===== ========================================================= ==================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
===== =============================================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
===== ========================================================= ==================================================
b) Nature of the Increase in interest in American Depository
transaction Shares following the re-investment of dividends
paid to shareholders on 11 April 2019 on
American Depository Shares held in the
Company's Deferred Annual Bonus Plan.
===== ========================================================= ==================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
$ 40.9400 538.000
----------
===== ========================================================= ==================================================
d) Aggregated information
Aggregated volume n/a (single transaction)
Price
===== ========================================================= ==================================================
e) Date of the transaction 2019-04-12
===== ========================================================= ==================================================
f) Place of the New York Stock Exchange (XNYS)
transaction
===== ========================================================= ==================================================
1. Details of PDMR/person closely associated with them
('PCA')
======================================================================
a) Name Mr R G Connor
=== ========================= ===========================================
b) Position/status President, Global Vaccines
=== ========================= ===========================================
c) Initial notification/ Initial notification
amendment
=== ========================= ===========================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================
a) Name GlaxoSmithKline plc
=== ========================= ===========================================
b) LEI 5493000HZTVUYLO1D793
=== ========================= ===========================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ========================= ===========================================
b) Nature of the Increase in interest in Ordinary Shares
transaction following the re-investment of dividends
paid to shareholders on 11 April 2019
on Ordinary Shares held in the Company's
Deferred Annual Bonus Plan.
=== ========================= ===========================================
c) Price(s) and volume(s) Price(s) Volume(s)
----------
GBP15.6560 238.000
----------
GBP15.6560 135.000
----------
GBP15.6560 193.000
----------
GBP15.6560 135.000
----------
=== ========================= ===========================================
d) Aggregated information
Aggregated volume 701.000
Price GBP15.6560
=== ========================= ===========================================
e) Date of the transaction 2019-04-12
=== ========================= ===========================================
f) Place of the transaction London Stock Exchange (XLON)
=== ========================= ===========================================
1. Details of PDMR/person closely associated with them ('PCA')
=========================================================================
a) Name Mr S P Dingemans
=== ======================== ===============================================
b) Position/status Executive Director
=== ======================== ===============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ===============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ===============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ===============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ===============================================
b) Nature of the Increase in interest in Ordinary Shares
transaction following the re-investment of dividends
paid to shareholders on 11 April 2019 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan.
=== ======================== ===============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.6560 649.000
----------
GBP15.6560 236.000
----------
GBP15.6560 645.000
----------
GBP15.6560 236.000
----------
=== ======================== ===============================================
d) Aggregated information
Aggregated volume 1766.000
Price GBP15.6560
=== ======================== ===============================================
e) Date of the transaction 2019-04-12
=== ======================== ===============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ===============================================
1. Details of PDMR/person closely associated with them
('PCA')
==========================================================================
a) Name Mr J Ford
=== ======================== ================================================
b) Position/status SVP and General Counsel
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
=== ======================== ================================================
b) Nature of the Increase in interest in American Depository
transaction Shares following the re-investment of dividends
paid to shareholders on 11 April 2019 on
American Depository Shares held in the
Company's Deferred Annual Bonus Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
$ 40.9400 46.000
----------
=== ======================== ================================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ================================================
e) Date of the transaction 2019-04-12
=== ======================== ================================================
f) Place of the New York Stock Exchange (XNYS)
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=========================================================================
a) Name Mr N Hirons
=== ======================== ===============================================
b) Position/status SVP, Global Ethics & Compliance
=== ======================== ===============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ===============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ===============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ===============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ===============================================
b) Nature of the Increase in interest in Ordinary Shares
transaction following the re-investment of dividends
paid to shareholders on 11 April 2019 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan.
=== ======================== ===============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.6560 99.000
----------
GBP15.6560 85.000
----------
GBP15.6560 101.000
----------
GBP15.6560 85.000
----------
=== ======================== ===============================================
d) Aggregated information
Aggregated volume 370.000
Price GBP15.6560
=== ======================== ===============================================
e) Date of the transaction 2019-04-12
=== ======================== ===============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ===============================================
1. Details of PDMR/person closely associated with them
('PCA')
==========================================================================
a) Name Mr B McNamara
=== ======================== ================================================
b) Position/status CEO, GSK Consumer Healthcare
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
=== ======================== ================================================
b) Nature of the Increase in interest in American Depository
transaction Shares following the re-investment of dividends
paid to shareholders on 11 April 2019 on
American Depository Shares held in the
Company's Deferred Annual Bonus Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
$ 40.9400 90.000
----------
$ 40.9400 98.000
----------
$ 40.9400 96.000
----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume
Price
284.000
$ 40.9400
=== ======================== ================================================
e) Date of the transaction 2019-04-12
=== ======================== ================================================
f) Place of the New York Stock Exchange (XNYS)
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=========================================================================
a) Name Mr L Miels
=== ======================== ===============================================
b) Position/status President, Global Pharmaceuticals
=== ======================== ===============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ===============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ===============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ===============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ===============================================
b) Nature of the Increase in interest in Ordinary Shares
transaction following the re-investment of dividends
paid to shareholders on 11 April 2019 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan.
=== ======================== ===============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.6560 253.000
----------
GBP15.6560 183.000
----------
=== ======================== ===============================================
d) Aggregated information
Aggregated volume 436.000
Price GBP15.6560
=== ======================== ===============================================
e) Date of the transaction 2019-04-12
=== ======================== ===============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ===============================================
1. Details of PDMR/person closely associated with them
('PCA')
=====================================================================
a) Name Mr D Redfern
=== ======================== ===========================================
b) Position/status Chief Strategy Officer
=== ======================== ===========================================
c) Initial notification/ Initial notification
amendment
=== ======================== ===========================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =====================================================================
a) Name GlaxoSmithKline plc
=== ======================== ===========================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ===========================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =====================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ===========================================
b) Nature of the Increase in interest in Ordinary Shares
transaction following the re-investment of dividends
paid to shareholders on 11 April 2019
on Ordinary Shares held in the Company's
Deferred Annual Bonus Plan.
=== ======================== ===========================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.6560 225.000
----------
GBP15.6560 107.000
----------
GBP15.6560 187.000
----------
GBP15.6560 107.000
----------
=== ======================== ===========================================
d) Aggregated information
Aggregated volume 626.000
Price GBP15.6560
=== ======================== ===========================================
e) Date of the transaction 2019-04-12
=== ======================== ===========================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ===========================================
1. Details of PDMR/person closely associated with them ('PCA')
========================================================================
a) Name Mr R Simard
=== ======================= ===============================================
b) Position/status President, Pharmaceuticals Supply Chain
=== ======================= ===============================================
c) Initial notification/ Initial notification
amendment
=== ======================= ===============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ========================================================================
a) Name GlaxoSmithKline plc
=== ======================= ===============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================= ===============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ========================================================================
a) Description Ordinary shares of 25 pence each ('Ordinary
of the financial Shares')
instrument ISIN: GB0009252882
=== ======================= ===============================================
b) Nature of the Increase in interest in Ordinary Shares
transaction following the re-investment of dividends
paid to shareholders on 11 April 2019 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan.
=== ======================= ===============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.6560 81.000
----------
=== ======================= ===============================================
d) Aggregated information
Aggregated volume n/a (single transaction)
Price
=== ======================= ===============================================
e) Date of the 2019-04-12
transaction
=== ======================= ===============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================= ===============================================
1. Details of PDMR/person closely associated with them
('PCA')
==========================================================================
a) Name Ms K Terrell
=== ======================== ================================================
b) Position/status Chief Digital & Technology Officer
=== ======================== ================================================
c) Initial notification/ Initial notification
amendment
=== ======================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ==========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ==========================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
=== ======================== ================================================
b) Nature of the Increase in interest in American Depository
transaction Shares following the re-investment of dividends
paid to shareholders on 11 April 2019 on
American Depository Shares held in the
Company's Deferred Annual Bonus Plan.
=== ======================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
$ 40.9400 114.000
----------
$ 40.9400 32.000
----------
=== ======================== ================================================
d) Aggregated information
Aggregated volume 146.000
Price
$ 40.9400
=== ======================== ================================================
e) Date of the transaction 2019-04-12
=== ======================== ================================================
f) Place of the New York Stock Exchange (XNYS)
transaction
=== ======================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
=========================================================================
a) Name Mr P C Thomson
=== ======================== ===============================================
b) Position/status President, Global Affairs
=== ======================== ===============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ===============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ===============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ===============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ===============================================
b) Nature of the Increase in interest in Ordinary Shares
transaction following the re-investment of dividends
paid to shareholders on 11 April 2019 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan.
=== ======================== ===============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.6560 131.000
----------
GBP15.6560 102.000
----------
GBP15.6560 126.000
----------
=== ======================== ===============================================
d) Aggregated information
Aggregated volume 359.000
Price GBP15.6560
=== ======================== ===============================================
e) Date of the transaction 2019-04-12
=== ======================== ===============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ===============================================
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHQQLFFKZFXBBX
(END) Dow Jones Newswires
April 16, 2019 12:35 ET (16:35 GMT)
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De May 2023 a May 2024
